<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23375">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895413</url>
  </required_header>
  <id_info>
    <org_study_id>CTM_LESÃO ARTICULAR-461/2010</org_study_id>
    <secondary_id>CTM_LESÃO ARTICULAR-461/2010</secondary_id>
    <nct_id>NCT01895413</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair</brief_title>
  <official_title>Autologous Bone Marrow-derived Mesenchymal Stem Cells Used in the Treatment of Articular Cartilage Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paulo Brofman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontifícia Universidade Católica do Paraná</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consultório Médico Dr. Alcy Vilas Boas Jr., Paraná, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Marcelino Champagnat, Paraná, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Araucária, Paraná, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontifícia Universidade Católica do Paraná</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Brazil: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized study aimed to determine the safety and efficacy of intra-articular
      injection of autologous bone marrow-derived mesenchymal stem cells in patients with knee
      articular cartilage defects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis is the most prevalent joint disease, create articular cartilage defects is a
      frequent cause of joint pain, functional loss, and disability. Osteoarthritis often becomes
      chronic, and conventional treatments seek to ameliorate pain or improve mobility. However,
      these treatments rarely modify the course of the disease.Recent studies cell-based have
      shown encouraging results in both animal studies and a few human case reports.  We designed
      a study to assess the safety and efficacy of osteoarthritis treatment with intra-articular
      injection of autologous bone marrow-derived mesenchymal stem cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in WOMAC (Western Ontário and MacMaster Universities)score</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cartilage thickness at 6 months by MRI</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain relief (WOMAC and Lequesne scores)</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspiration</intervention_name>
    <description>Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy</description>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with mild to moderate osteoarthritis (visual analogue scale)

          -  History of joint swelling, pain, stiffness, altered gait and loss of motion due to
             degenerative cartilage

        Exclusion Criteria:

          -  Any past history of neoplasia and primary hematological disease

          -  Autoimmune disease or the medical history

          -  Systemic bone or cartilage disorders

          -  Acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV

          -  Co-morbidity which the physician deems as a contraindication to stem cell
             transplantation and bone marrow biopsy

          -  Evidence of infection or fractures in or around the joint

          -  Contraindication to bone marrow aspiration

          -  Deviation from the axial axis (varus or valgus) greater than 12 degrees.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Brofman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontifícia Universidade Católica do Paraná</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulo Brofman, PhD</last_name>
    <phone>+55 41 3271 2219</phone>
    <email>paulo.brofman@pucpr.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Senegaglia, PhD</last_name>
    <phone>+55 41 3271 2219</phone>
    <email>alexandra.senegaglia@pucpr.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Tecnologia Celular, Pontifícia Universidade Católica do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80215-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Senegaglia, PhD</last_name>
      <phone>+55 41 32712219</phone>
      <email>alexandra.senegaglia@pucpr.br</email>
    </contact>
    <investigator>
      <last_name>Paulo Brofman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Senegaglia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Rebelatto, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Malheiros, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debora Daga, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alcy Vilas Boas Jr, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamara Borgonovo, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Jackowski, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gisele Sonda, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leticia Fracaro, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Bocassanta, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 10, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pontifícia Universidade Católica do Paraná</investigator_affiliation>
    <investigator_full_name>Paulo Brofman</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Cartilage injury</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
